Medherant

The company’s core technology is the TEPI Patch®, a proprietary drug-in-adhesive platform designed for the controlled release of pharmaceuticals through the skin. This technology utilizes a unique pressure-sensitive adhesive that allows for a high drug-loading capacity, enabling the delivery of a wider range of drugs and higher doses than many existing patches. The drug is mixed directly into the adhesive matrix, which ensures consistent and controlled release. The patches are designed to be thin, flexible, comfortable, and leave no residue upon removal. The manufacturing process is solvent-free, making it more efficient and scalable.

Medherant's business model has two main approaches: developing its own pipeline of products for future licensing and collaborating with pharmaceutical partners to formulate their existing drugs for transdermal delivery. A collaboration with Bayer to develop a transdermal patch for an approved oral medicine was announced in March 2024. The company generates revenue through these partnerships, with expectations of future milestone payments and licensing revenues. Its lead product is a testosterone patch for treating Hypoactive Sexual Desire Disorder (HSDD) in post-menopausal women, a significant unmet medical need. In October 2025, the company announced positive results from a Phase I clinical trial for its testosterone patch, which successfully restored testosterone levels to the normal pre-menopausal range.

Medherant has secured funding from investors including Mercia Asset Management, the British Business Bank, and private investors. As of April 2023, the company had raised a total of $13.5 million over six funding rounds. Keywords: transdermal drug delivery, TEPI Patch, polymer chemistry, bioadhesives, pharmaceutical development, clinical-stage company, drug-in-adhesive, testosterone patch, women's health, HSDD, controlled release, Mercia Asset Management, David Haddleton, University of Warwick spin-off, pain management, CNS diseases, solvent-free manufacturing, intellectual property, product licensing, pharmaceutical partnerships